Oppenheimer analysts adjusted their outlook on Ingredion stock (NYSE: NYSE:INGR), reducing the price target from $178.00 to $167.00, while maintaining an Outperform rating. The modification follows a ...

Christopher Nolan’s next project is an adaptation of The Odyssey, and though Oppenheimer is his biggest project to date, his ...

Oppenheimer (NYSE:OPY – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Monday. Oppenheimer Trading ...

The card collecting industry has exploded in recent years to such an extent that industry leader Topps is now producing a Robert Oppenheimer card that's ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

Benny Safdie is the latest actor to join the cast of The Odyssey, the next movie from Christopher Nolan, according to The ...

Oppenheimer downgraded Apple from "outperform" to "perform" because it is struggling to adapt to a competitive AI landscape.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that ...

British consumers’ appetite for home entertainment reached new heights in 2024, with the sector surpassing £5.1 billion ($6.4 ...

Reports Q4 revenue $375.4M vs. $308.3M last year. AUM;was $49.4B vs. $43.9B last year. CEO Albert Lowenthal commented, “The Firm registered ...

Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering ...